Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The DNA damage response (DDR) pathway and its core component tumor suppressor p53 block cell cycle progression after genotoxic stress and represent an intrinsic barrier preventing cancer development. The serine/threonine phosphatase PPM1D/Wip1 inactivates p53 and promotes termination of the DDR pathway. Wip1 has been suggested to act as an oncogene in a subset of tumors that retain wild-type p53. In this paper, we have identified novel gain-of-function mutations in exon 6 of PPM1D that result in expression of C-terminally truncated Wip1. Remarkably, mutations in PPM1D are present not only in the tumors but also in other tissues of breast and colorectal cancer patients, indicating that they arise early in development or affect the germline. We show that mutations in PPM1D affect the DDR pathway and propose that they could predispose to cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. The PPM1D gene is mutated in selected cancer cell lines. (A) Whole-cell lysates from indicated cell lines were probed with anti-Wip1 (Bethyl Laboratories, Inc.), anti-Wip1 (Santa Cruz Biotechnology, Inc. [SC]), and anti–14-3-3 (loading control) antibodies. Note the additional Wip1-reactive band around 60 kD in U2OS and HCT116 cells. PC3 cells are p53 negative and served as a control. (B) Wip1 was depleted in U2OS and HCT116 cells by siRNA, and lysates were probed with the indicated antibodies. (C) Sequencing chromatograms of PPM1D from genomic DNA isolated from U2OS and HCT116 cells. Numbering is based on NCBI GenBank reference sequence NT_010783.15. Mutations are indicated by arrowheads and underlined. WT, wild-type PPM1D; Mut, mutated PPM1D; c., nucleotide sequence; p., Wip1 peptide sequence.](https://figures.cochat.ai/paper-figures/a55e0889191c480d83b569a3230ebde9/gain-of-function-mutations-of-ppm1d-wip1-impair-the-p53-dependent-g1-checkpoint-figure-1.jpg)

![Figure 3. Truncated Wip1 mutants show increased protein stability. (A) HCT116 and U2OS cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed using the monoclonal anti-Wip1 antibody (Santa Cruz Biotechnology, Inc. [SC]). (B) Signal intensity corresponding to the FL-Wip1 and truncated Wip1 from A was quantified using ImageJ software. The relative change in signal intensity is shown. Statistical significance was determined by unpaired two-tailed t test (n = 3; *, P < 0.05). (C) U2OS cells were treated with cycloheximide, proteasomal inhibitor MG132 or a combination of both for the indicated times and analyzed as in A. (D) U2OS cells were transfected with plasmid DNA coding for EGFP or EGFP fused to the C-terminal region of Wip1 (aa 380–605). Cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed with an anti-GFP antibody, and the signal intensity was quantified using ImageJ software. n = 3. Error bars indicate standard deviations. exp., exposure.](https://figures.cochat.ai/paper-figures/1244c669d3094b87aac15d5705c32b4a/gain-of-function-mutations-of-ppm1d-wip1-impair-the-p53-dependent-g1-checkpoint-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this p53/pRb proficient cell line, p21 induction is impaired due to inefficient ATM response 72 and, probably, mutation of the Wip1 phosphatase that interferes with p53 activation.97”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · cited 2×
“Although high doses of DNA damage (such as therapeutic irradiation or radiomimetic drugs) lead to p53-induced programmed cell death or permanent withdrawal from the cell cycle (senescence), more moderate DNA damage (originating from erroneous DNA metabolism or from environmental factors) triggers expression of DNA rep…”
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“The most common example of such DDR defect is an inactivating somatic mutation in the TP53 gene that disables proper response to genotoxic stress, leads to genomic instability, and is found in about half of human tumors (Hollstein et al., 1991).”
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“In general, genotoxic stress induces stabilization, oligomerization, and binding of p53 to promoters, causing a widespread modulation of gene expression (Vogelstein et al., 2000).”
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 2×
“…ATM (ataxia telangiectasia mutated)/Chk2, ATR (ataxia telangiectasia and Rad3 related)/Chk1, and p38/ MK2 kinases converges on the tumor suppressor p53, which plays a central role in regulating cell fate decisions in response to genotoxic stress (Jackson and Bartek, 2009; Medema and Macůrek, 2012).”
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“Whereas tumor development is substantially boosted by inactivation of the second allele of the tumor suppressor genes, monoallelic gain-offunction mutations are usually sufficient to activate oncogenes (Vogelstein and Kinzler, 2004).”
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 2×
“…identified oncogene-induced replication stress and DNA breakage that trigger the DDR as an intrinsic barrier against progression of early preinvasive stages of solid tumors to malignant lesions (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005; Di Micco et al., 2006; Halazonetis et al., 2008).”
Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression
Sakaue-Sawano, A., Kurokawa, H., Morimura, T., Hanyu, A., Hama, H., Osawa, H., Kashiwagi, S., Fukami, K., Miyata, T., Miyoshi, H., et al. (2008) · Cell · doi:10.1016/j.cell.2007.12.033 · Cited by 2,173 · cited 2×
“A stable cell line expressing the fluorescent, ubiquitination-based cell cycle indicator (FUCCI) was generated by transduction of HCT116 cells with pCSII-EF-MCS-mKO2hCdt1(30–120) and pCSII-EF-MCS-mAG-hGeminin(1–110) plasmids (Sakaue-Sawano et al., 2008) followed by FACS sorting of double-positive cells from which a si…”
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×
“…identified oncogene-induced replication stress and DNA breakage that trigger the DDR as an intrinsic barrier against progression of early preinvasive stages of solid tumors to malignant lesions (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005; Di Micco et al., 2006; Halazonetis et al., 2008).”
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966 · cited 1×
“For example, germline mutations of oncogenic tyrosine kinases RET, MET, and KIT are linked with medullary thyroid carcinoma, hereditary papillary renal carcinoma, and hereditary gastrointestinal stromal tumor syndrome, respectively (Mulligan et al., 1993; Schmidt et al., 1997; Nishida et al., 1998).”
Cited by
Items 101–173 of 173
Kozakai, Y., Kamada, R., Kiyota, Y., Yoshimura, F., Tanino, K., & Sakaguchi, K. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.093 · Cited by 10
Kim, B., Won, D., Lee, S., & Choi, J. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217521 · Cited by 10
A novel assay for screening WIP1 phosphatase substrates in nuclear extracts
Storchova, R., Burdová, K., Palek, M., Medema, R. H., & Macůrek, L. (2021) · FEBS Journal · doi:10.1111/febs.15965 · Cited by 9
Self-citationClonal haematopoiesis - a novel entity that modifies pathological processes in elderly
Belotserkovskaya, E., Golotin, V., Uyanik, B., & Demidov, O. N. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01590-z · Cited by 9
“The majority of PPM1D mutations in clonal haematopoiesis are located in the last two exons [6], which leads to the loss of the regulatory domain of the product of this gene, serine-threonine phosphatase Wip1 [31].”
BackgroundKato, H., Maezawa, Y., Nishijima, D., Iwamoto, E., Takeda, J., Kanamori, T., Yamaga, M., Mishina, T., Takeda, Y., Izumi, S., et al. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.02.005 · Cited by 8
Detectible mosaic truncating PPM1D mutations, age and breast cancer risk
Machiela, M. J., Myers, T. A., Lyons, C. J., Koster, R., Figg, W. D., Colli, L. M., Jessop, L., Ahearn, T. U., Freedman, N. D., García‐Closas, M., et al. (2019) · Journal of Human Genetics · doi:10.1038/s10038-019-0589-1 · Cited by 8
Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple Myeloma
Seipel, K., Veglio, N. Z., Nilius, H., Jeker, B., Bacher, U., & Pabst, T. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080484 · Cited by 7
“PPM1D gene alterations entail nonsense and frameshift mutations, creating early stop codons [13,14].”
BackgroundWu, K., Ge, X.-X., Duan, X.-F., Li, J.-Q., Wang, K., Chen, Q., Huang, Z.-M., Zhang, W., Wu, Y., & Li, Q. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101196 · Cited by 7
Li, Z., Du, C., Zhang, C., Zhang, M., Ying, Y., Liang, Y., & Luo, X. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1120 · Cited by 7
“PPM1D amplification or gain-offunction variant can reduce the synthesis of relevant phosphatase, which affects activities of cell proliferation and thus leads to the occurrence of disease (Jansen et al., 2017; Kleiblova et al., 2013).”
BackgroundExploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors
Murray, M. A., Noronha, K. J., Wang, Y., Friedman, A. P., Paradkar, S., Suh, H., Sundaram, R. K., Brenner, C., Saltzman, W. M., & Bindra, R. S. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0012 · Cited by 7
Milosevic, J., Fransson, S. M., Svensson, J., Otte, J., Olsen, T. K., Sveinbjørnsson, B., Hertwig, F., Bartenhagen, C., Abel, F., Reinsbach, S. E., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217769 · Cited by 6
Lu, X., Ng, K., Vairo, F. P. E., Collins, J., Cohn, R. D., Riley, K. N., Agre, K. E., Gavrilova, R. H., Klee, E. W., Rosenfeld, J. A., et al. (2024) · European Journal of Human Genetics · doi:10.1038/s41431-024-01576-0 · Cited by 6
“The similar mechanism has been described for PPM1D truncating mutations associated NDD [14].”
BackgroundMartinikova, A. S., Burócziová, M., Stoyanov, M., & Macůrek, L. (2020) · Cells · doi:10.3390/cells9092068 · Cited by 8
“Importantly, deletion of the C-terminal tail leaves the catalytic domain of PPM1D intact and also preserves chromatin localization of the truncated protein [31].”
BackgroundResultPPM1D activity promotes the replication stress caused by cyclin E1 overexpression
Martinikova, A. S., Stoyanov, M., Oravetzova, A., Kok, Y. P., Yu, S., Dobrovolná, J., Janščák, P., van Vugt, M. A. T. M., & Macůrek, L. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13433 · Cited by 6
Menendez-Gonzalez, J. B., & Rodrigues, N. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_5 · Cited by 6
The Harmful Consequences of Increased Fitness in Hematopoietic Stem Cells
McNerney, M. E., & Beau, M. M. L. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.10.003 · Cited by 5
Genome-Protective Topoisomerase 2a-Dependent G2 Arrest Requires p53 in hTERT-Positive Cancer Cells
Lockwood, N., Martini, S., Lopez-Pardo, A., Deiss, K., Segeren, H. A., Semple, R. K., Collins, I., Repana, D., Cobbaut, M., Soliman, T. N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1785 · Cited by 5
“U2OS cells are p53 WT, but they have an active, truncated form of the phosphatase Wip1 (34), which we confirmed is present in our U2OS cell line (Supplementary Fig.”
BackgroundSOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells
Zhang, L., Hsu, J. I., Braekeleer, E. D., Chen, C.-W., Patel, T. D., Martell, A. G., Guzman, A. G., Wohlan, K., Waldvogel, S. M., Urya, H., et al. (2023) · eLife · doi:10.1101/2023.08.31.555634 · Cited by 5
“Our results showed similar levels of repair via HR in both WT and mutant clones ( Figure 5C ).”
Crystal structure and mechanistic studies of the PPM1D serine/threonine phosphatase catalytic domain
Kumar, J. P., Košek, D., Durell, S. R., Jenkins, L. M. M., Debnath, S., Coussens, N. P., Hall, M. D., Appella, D. H., Dyda, F., Mazur, S. J., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107561 · Cited by 4
A Case Study on PPM1D and 9 Other Shared Germline Alterations in a Family
Biswas, S., Manekar, S. C., & Bakshi, S. R. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.6.2129 · Cited by 4
“All the mutations were associated with the truncation of Wip1 proteins p.R458X, p.L484X, p.K535X, and p.F534X leading to P53 impairment (Kleiblova et al., 2013).”
BackgroundDiffuse Intrinsic Pontine Glioma
Valvi, S., & Gottardo, N. G. (2018) · InTech eBooks · doi:10.5772/intechopen.78578 · Cited by 5
Smaller Protein, Larger Therapeutic Potential: PPM1D as a New Therapeutic Target in Brainstem Glioma
Reitman, Z. J. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.123 · Cited by 4
Karlıtepe, A., Altın, E. D., Ak, C., Bilmen, S., & Eren, M. K. (2023) · Gene Reports · doi:10.1016/j.genrep.2023.101784 · Cited by 3
Alternative Lengthening of Telomeres: The Need for ATRX Mutations Is Lineage-Dependent
Udroiu, I., & Sgura, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146765 · Cited by 4
“However, Kleiblova et al. [33] finally identified a gain-of-function mutation of PPM1D in U2OS that impairs the p53 pathway.”
WIP1 mutations suppress DNA damage triggered bypass of the mitotic timer
Sobajima, T., Fulcher, L. J., Batley, C., Alsop, S. J., Veakins, J., & Barr, F. A. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00495-0 · Cited by 3
“In agreement with previous studies on cancer cell lines with WIP1 mutations (Kahn et al, 2018; Kleiblova et al, 2013), WIP1 Δ CT has a longer half-life and is more abundant than the normal WIP1 protein (Fig.”
Enter the nucleus to exit the cycle
Krenning, L., & Medema, R. H. (2014) · Cell Cycle · doi:10.4161/15384101.2014.948783 · Cited by 3
Self-citationMolecular Wanderings Through the DNA Damage Response and Risk for Ovarian Cancer
Bookman, M. A. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt350 · Cited by 3
“PPM1D appears to function as a negative regulator of p53 (3) and could generate an internal knockdown of p53 function, contributing to platinum resistance in tumors that retain p53 (4).”
BackgroundTakahashi, M., Kondo, T., Kimura, S., Nakazono, A., Yoshida, S., Wada, T., Watanabe, M., & Hatakeyama, S. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01185-z · Cited by 2
“Previous studies have reported that the C-terminal truncation mutant of PPM1D exhibits enhanced stability compared to its wild-type counterpart [4].”
Cancer treatment alters mutant selection in normal esophagus
Fowler, J. C., Arbore, G., Sood, R. K., Abnizova, I., Albarello, L., Pickering, O. J., Murai, K., Banerjee, U., Brunon, S., Ong, S. H., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02738-0 · Cited by 2
“Such mutants generate a stabilized form of the protein that retains phosphatase activity, inhibiting TP53 function, activating MTORC1 and conferring resistance to chemotherapy and ionizing radiation in mutant hematopoietic stem cells, leading to clonal hematopoiesis 8,9,29–32 .”
Shaltiël, I. A., Llopis, A., Aprelia, M., Klompmaker, R., Menegakis, A., Krenning, L., & Medema, R. H. (2021) · Cells · doi:10.3390/cells10030550 · Cited by 2
“We have previously shown that the DNA damage response in G1 is lost in commonly used p53-proficient cancer cell lines [29], but is retained in immortalized non-transformed human retinal pigment epithelial cells (RPE-1) [26].”
BackgroundSelf-citationDevelopment of Antibody-like Proteins Targeting the Oncogenic Ser/Thr Protein Phosphatase PPM1D
Ikeura, M., Tashiro, H., Yamagata, Y., Saito, H., Kobayashi, T., Mizunuma, M., Yamazaki, K., Baba, K., Furukawa, K., & Chuman, Y. (2022) · Processes · doi:10.3390/pr10081501 · Cited by 2
Liu, Y., Xia, F., Zhu, C., Song, J., Tang, B., Zhang, B., & Huang, Z. (2024) · Theranostics · doi:10.7150/thno.104529 · Cited by 2
“Furthermore, increased expression of truncated PPM1D also leads to reduction of phosphorylated H2AX, and impairs the P53-mediated G1 cell arrest in breast and colorectal cancer (CRC) [77].”
An ATM-PPM1D circuit controls the processing and restart of DNA replication forks
Cao, Y., Wang, Y., Badar, J., Jaber, K., Faça, V. M., Huang, T., Çelik, E., & Smolka, M. B. (2026) · EMBO Reports · doi:10.1101/2025.05.13.652823 · Cited by 2
Jeong, H. J., Woo, C. G., Lee, B., Khang, S. K., Nam, S. J., & Choi, J. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.10.21 · Cited by 2
“Activated PPM1D directly dephosphorylates Chk1, Chk2, p38 mitogen-activated protein kinase, uracil DNA glycosylase, MDM2, H2AX, and p53, suggesting that it acts as a homeostatic regulator.(19-22) The PPM1D gene is frequently amplified/overexpressed in various human cancers, all of which rarely carry a p53 mutation.”
Klonale Hämatopoese – Teil 1: Entwicklung und Malignomrisiko
Haase, D. T. (2019) · best practice onkologie · doi:10.1007/s11654-019-0141-y · Cited by 2
“Aktivie- rende Mutationen in PPM1D, einem wichtigen negativen TP53Regulator, treten eher bei nichthämatologischen Neoplasien auf und führen zu einer Beeinträchtigung von TP53-Funktionen [15, 21].”
BackgroundImpact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Panagiota, V., Meggendorfer, M., Kubasch, A. S., Gabdoulline, R. R., Krönke, J., Mies, A., Shahswar, R., Kandziora, C., Klement, P., Schiller, J., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26162 · Cited by 2
PPM1D is a neuroblastoma oncogene and therapeutic target in childhood neural tumorsPreprint
Milosevic, J., Fransson, S. M., Gulyás, M., Gallo-Oller, G., Olsen, T. K., Treis, D., Wickström, M., Elfman, L. H. M., Sveinbjørnsson, B., Hertwig, F., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.04.283648 · Cited by 2
DNA Damage Response and Autophagy: An Exclusive Meeting in Cancer
Eren, M. K. (2020) · International Journal of Innovative Approaches in Science Research · doi:10.29329/ijiasr.2020.312.7 · Cited by 1
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development
Fedorov, K., Luo, L. Y., Bick, A. G., & Savona, M. R. (2025) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-025-00768-9 · Cited by 1
“Most pathologic variants in PPM1D gene located on chromosome 17q are somatic truncating muta - tions in exon 6 that precludes proteasomal degradation while maintaining proteolytic activity [61].”
Bertrand, A., Page, S. L., Pirabakaran, V., Kermasson, L., Brunet, E., Donadieu, J., Gleizes, P., O’Donohue, M.-F., & Revy, P. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01476-7 · Cited by 1
RNF126 and BRAP safeguard genome integrity after DNA damage in late mitosis
Ayra‐Plasencia, J., Jorge, I., Vázquez, J., Freire, R., & Smits, V. A. J. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117279 · Cited by 1
Combined inhibition of PLK4 and PPM1D promotes cell death in cancer cells with 17q amplification
Stoyanov, M., Aquino-Perez, C., Mazumder, S., Salcakova, D., Petrezsélyová, S., & Macůrek, L. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04391-3 · Cited by 1
“Finally, we tested the effect of centrinone on sensitivity of U2OS cells that contain high levels of active PPM1D due to the gain-of-function mutation in the last exon of PPM1D gene but do not show amplification of the 17q locus [38].”
Clonal hematopoiesis in telomere biology disorders
Sande, C. M., & Babushok, D. V. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.02.004 · Cited by 1
Leslie, M. (2013) · The Journal of Cell Biology · doi:10.1083/jcb.2014if
The interaction between Rad9 and Tousled-like kinase 1 in the cell cycle and the DNA damage response
Kelly, R. M. (2013) · QSpace (Queen's University Library)
Epileptic encephalopathy caused by biallelic mutation in PPM1D: a case report
AlMaghthawi, H., Nashabat, M., & Alfadhel, M. (2018) · Journal of Biochemical and Clinical Genetics · doi:10.24911/jbcgenetics/183-1532438227
Santos, F. P. D. S. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-03072020-160625
Targeting MDM2, the antagonist of the tumor suppressor p53
Sriraman, A. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7056 · Cited by 2
Faculty Opinions recommendation of Persistent repair intermediates induce senescence.
Golemis, E. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734083424.793554766
Aguilan, J. T., Pedrosa, E., Dolstra, H., Baykara, R. N., Barnes, J., Zhang, J., Sidoli, S., & Lachman, H. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.08.548192 · Cited by 1
Using team-based precision medicine to advance understanding of rare genetic brain disorders
Walkley, S. U., Molholm, S., Jordan, B. A., Marion, R. W., & Wasserstein, M. (2024) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-024-09518-z
“However, the half-life is extended because of the loss of a proteasomal targeting and degradation signal at the C-terminal end of the protein [25].”
BackgroundSOD1 is a synthetic lethal target in PPM1D-mutant leukemia cellsPreprint
Zhang, L., Hsu, J. I., Braekeleer, E. D., Chen, C.-W., Patel, T. D., Martell, A. G., Guzman, A. G., Wohlan, K., Waldvogel, S. M., Urya, H., et al. (2024) · eLife · doi:10.7554/elife.91611.2 · Cited by 1
PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas
Pilevneli, H., Döger, F. K., Karagenç, L., Kozacı, L. D., & Eren, M. K. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10029-2
“PPM1D gene amplifications and mutations as well as its overexpression have been reported in human cancers [12–14 , 30].”
Rôle de la phosphatase Wip1 dans la nécroptose
Lagorgette, L. (2024) · theses.fr (ABES) · doi:10.70675/b5a83307z526dz44e4zb095z5284b2c79c3c
Janin, M. (2024) · ASEAN Journal of Psychiatry · doi:10.54615/2231-7805.440
Eldomery, M. K., Jones, K. M. D., Namwanje, M., Kumar, R. D., Li, J., Wilkinson, M. R., Wang, L., Klco, J. M., Li, T., Neary, J. L., et al. (2025) · medRxiv · doi:10.1101/2025.11.20.25340490
Additional file 2 of Prevalence, causes and impact of TP53-loss phenocopying events in human tumors
Fito-Lopez, B., Salvadores, M., Alvarez, M.-M., & Supek, F. (2024) · Figshare · doi:10.6084/m9.figshare.26584569
Additional file 4 of Prevalence, causes and impact of TP53-loss phenocopying events in human tumors
Fito-Lopez, B., Salvadores, M., Alvarez, M.-M., & Supek, F. (2024) · Figshare · doi:10.6084/m9.figshare.26584575
Additional file 3 of Prevalence, causes and impact of TP53-loss phenocopying events in human tumors
Fito-Lopez, B., Salvadores, M., Alvarez, M.-M., & Supek, F. (2024) · Figshare · doi:10.6084/m9.figshare.26584572
Additional file 1 of Prevalence, causes and impact of TP53-loss phenocopying events in human tumors
Fito-Lopez, B., Salvadores, M., Alvarez, M.-M., & Supek, F. (2024) · Figshare · doi:10.6084/m9.figshare.26584566
A Deubiquitinating Enzyme as a Therapeutic Target in Sonic Hedgehog Medulloblastoma
Cigna, S. M. (2016) · theses.fr (ABES) · doi:10.70675/f9b5722ezb5dez481fzbb22z1bda74d90023
Evangelista, C. C. S. (2018) · theses.fr (ABES) · doi:10.70675/38a6ac60z57c9z47dcz9250z5b4555fef601
Nguyen, H. (2024) · theses.fr (ABES) · doi:10.70675/c70cdfa2ze652z4a28zaa4ez777acef97d0e · Cited by 1
Clonal Signatures of Telomere Biology Disorders
Arcuri, L., Groarke, E. M., Savage, S. A., & Gutierrez‐Rodrigues, F. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00777-2
“Recurrent selection of multiple ATM and PPM1D clones, a consequence of their emergence in independent HSPCs, are suggestive of strong selective pressure driven by dysfunctional telomeres.”
Distinct Proteasomal Pathways Drive Oncogenic PPM1D ActivationPreprint
Yan, N., Shrestha, D., Schluter, C., Jin, C., Wang, E., Silva, C. D., Gritti, I., Tsopoulidis, N., Yang, R., Sperling, A. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.01.729344
“10,11,13,20,21 We employed the MOLM13 a cute myeloid leukemia cells, which is PPM1D wild-type and therefore expresses fl-PPM1D, to introduce indels into exon 6 of PPM1D at amino acid 495 via CRISPR/Cas9 to generate isogenic cells that express tr-PPM1D ( Figure 1C ).”
van der Weg, K., Bertschinger, M., Bacher, U., Hoffmann, M., Nilius, H., Seipel, K., & Pabst, T. (2026) · Cancers · doi:10.3390/cancers18132032
“In hematopoietic cells, PPM1D alterations predominantly consist of nonsense or frameshift mutations clustered in exon 6, resulting in C-terminally truncated protein products with preserved phosphatase activity and increased protein stability due to impaired proteasomal degradation [35,36].”
Luijts, T., Hoogstoel, S., Wen, S., Pappaert, E., Meester, E. D., Nieuwerburgh, F. V., Hamme, E. V., Schepper, S. D., Willaert, W., Vral, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.08.737173
Upregulation of ITM2A by p53 activation modulates p53 function through physical interaction
Namkoong, S., Jang, M., Lee, J. I., Lee, S., Park, R., Jeong, Y., Lee, E., & Park, J. (2026) · Cell Cycle · doi:10.1080/15384101.2026.2717663
Douglas, S. P. M., Kaaja, I., Ikonen, I., Langohr, L., Koski, J., Hakkarainen, M., Katainen, L., Barbany, G., Hellström‐Lindberg, E., Jahnukainen, K., et al. (2026) · medRxiv · doi:10.64898/2026.09.16.26363199
Rusin, M., Krześniak, M., & Łasut-Szyszka, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27208964
“Moreover, many p53 target genes could have been overlooked in previous high-throughput searches because the commonly employed cell lines (e.g., HCT116, U-2 OS) harbour gain-of-function mutations in the PPM1D gene, which is a negative regulator of p53 [61].”
Metadata
- Authors
- Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., Medema, R. H., & Macurek, L.
- Affiliations
- Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, CZ-12853 Prague, Czech Republic 1
- Division of Cell Biology, The Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands 2
- Czech Academy of Sciences (CZ)
- Charles University (CZ)
- University Medical Center Utrecht (NL)
- Department of Cancer Cell Biology 4 and 5
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Medema, René H.
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2013-05-06
- Volume
- 201
- Issue
- 4
- Pages
- 511-521
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC3653305
- OpenAlex
- W2096812573
- Cited by
- 170
- References
- 39
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 25 · 2023: 12 · 2022: 10 · 2021: 11 · 2020: 12 · 2019: 12 · 2018: 11 · 2017: 13 · 2016: 12 · 2015: 11 · 2014: 17 · 2013: 5
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Cell Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- ASEP (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- PPM1D, Wip1, gain-of-function mutations, p53, G1/S checkpoint, DNA damage response, tumor suppressor inactivation, breast cancer, colorectal cancer, germline mutations, cancer susceptibility, cell cycle arrest
- MeSH terms
- Protein Phosphatase 2C, Cell Cycle, DNA Damage, HeLa Cells, Humans, Mutation, Neoplasms, Phosphoprotein Phosphatases, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, G1 Phase, Genetic Predisposition to Disease, Cell Line, Tumor, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.